Detalhe da pesquisa
1.
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Proc Natl Acad Sci U S A
; 110(19): 7922-7, 2013 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23620515
2.
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Blood
; 121(13): 2533-41, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23361907
3.
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood
; 122(6): 1017-25, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23801631
4.
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat Chem Biol
; 8(11): 890-6, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23023262
5.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Biopharm Drug Dispos
; 35(4): 237-52, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415392
6.
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
Proc Natl Acad Sci U S A
; 107(49): 20980-5, 2010 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21078963
7.
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.
Cell Chem Biol
; 28(8): 1158-1168.e13, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33705687
8.
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Cancer Cell
; 39(9): 1214-1226.e10, 2021 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34375612
9.
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.
Int J Toxicol
; 29(1): 3-19, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903873
10.
Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells.
Clin Cancer Res
; 14(18): 5735-42, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18794082
11.
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Clin Cancer Res
; 13(24): 7237-42, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094401
12.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Mol Cancer Ther
; 6(1): 51-60, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17218635
13.
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Mol Cancer Ther
; 5(8): 1967-74, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16928817
14.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
J Clin Oncol
; 23(17): 3923-31, 2005 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897550
15.
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Clin Cancer Res
; 11(10): 3958-65, 2005 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897598
16.
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
J Med Chem
; 59(4): 1556-64, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26769278
17.
Histone deacetylase inhibitors.
Adv Cancer Res
; 91: 137-68, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15327890
18.
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Clin Cancer Res
; 9(15): 5749-55, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14654560
19.
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Clin Cancer Res
; 9(10 Pt 1): 3578-88, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14506144
20.
Histone deacetylases.
Curr Opin Pharmacol
; 3(4): 344-51, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12901942